Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions

NCT: NCT06476678 · RECRUITING

NCT IDNCT06476678
StatusRECRUITING
Start Date2024-10-15
Completion2027-12-31

Brief Summary

Both Baylor St Luke's Medical Center and Mayo Scottsdale are considered endoscopic submucosal dissection (ESD) centers of excellence. The investigators at Baylor College of Medicine have previously reported our Esophageal ESD experience using the monopolar current knife. Moreover, the research team have previously reported on the clinical efficacy of the bipolar RFA knife during per-oral endoscopic myotomy (POEM) and colonic ESD. The goal of our study is to prospectively evaluate the efficacy, safety and feasibility of Esophageal ESD using a novel Bipolar-Current ESD device.

Frequently Asked Questions

What is Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions?

Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions is a clinical trial registered under NCT06476678. Current status: RECRUITING.

What is the status of NCT06476678?

The current status of NCT06476678 (Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions) is: RECRUITING.

When did Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions start?

Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions started on 2024-10-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.